on (53)

Epizyme Appoints Jeffery Kutok, MD, PhD, as Chief Scientific Officer

Epizyme, Inc a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the company has appointed Jeffery Kutok, M.D., Ph.D., as chief scientific officer. In this role, Dr. Kutok will direct the company’s scientific strategy, including preclinical research to support the development expansion of TAZVERIK™ (tazemetostat) and the company’s epigenetic...